Printer Friendly

CORDIS INTRODUCES ADVANCED GUIDING CATHETERS

 CORDIS INTRODUCES ADVANCED GUIDING CATHETERS
 MIAMI, April 6 /PRNewswire/ -- Cordis Corporation


(NASDAQ-NMS: CORD) today announced the worldwide market release of two advanced guiding catheters: the 8F .084" XL Brite Tip and the 7F .072" Brite Tip. Designed to enhance the evolving angioplasty practice of interventional cardiologists, the new devices are used in conjunction with balloon catheters, which assist in opening coronary arteries occluded by the buildup of fatty deposits, or plaque, associated with atherosclerosis.
 Blending a proprietary nylon material with an innovative flex-coil design, the 8F .084" XL Brite Tip guiding catheter offers the largest inner lumen diameter (.084 inch) of any 8F guiding catheter available today. For the interventional cardiologist, this translates to:
 -- An ideal catheter for transporting the increasing array of new interventional devices now used to open blocked coronary vessels.
 -- Improved device versatility, decreasing the need for larger 9F systems that pose added risks for patients.
 -- Improved injection flow rates to enhance opacification and visualization, thus speeding up the procedure and reducing the exposure of physicians, technicians and patients to fluoroscopy.
 -- Improved backup support and flexibility that assist in getting the device properly positioned across the lesion(s), especially when deeply engaging the catheter within the coronary vasculature.
 Additional features of the device, which include a soft, radiopaque tip, are designed to meet other needs of interventional cardiologists.
 The 7F .072" Brite Tip guiding catheter, which includes many of the same features and benefits as the .084", is a second-generation device. Its inner lumen diameter (.072 inch) matches the largest currently available in any 7F guiding catheter.
 More than 90 percent of all balloon angioplasty procedures performed today involve the use of a 7F or 8F guiding catheter. Thus, Cordis' newest devices, which resided at the forefront of existing technology, should enhance the company's position as a major supplier of guiding catheters to interventional cardiologists throughout the world. The worldwide market for such devices totals $80 million, including some $50 million in the U.S.
 Miami-based Cordis Corporation manufactures and markets a variety of medical devices and systems for the angiographic and neuroscience markets. Shares of the company's stock are traded on the NASDAQ National Market under the symbol CORD.
 -0- 4/6/92
 /CONTACT: Chick McDowell, vice president of corporate relations and assistant secretary of Cordis Corporation, 305-824-2821/
 (CORD) CO: Cordis Corporation ST: Florida IN: HEA SU: PDT


JB-AW -- FL005 -- 5226 04/06/92 09:23 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 6, 1992
Words:401
Previous Article:ADVANCED VISUAL SYSTEMS INTRODUCES NEW VISUALIZATION SOFTWARE FOR DEVELOPERS, ENGINEERS, SCIENTISTS, BUSINESS PROFESSIONALS
Next Article:DRUG SCREENING SYSTEMS SUBMITS APPLICATION TO FDA FOR PCP TEST


Related Articles
CORDIS' SLEUTH ANGIOPLASTY CATHETER GAINS MARKET APPROVAL
CORDIS INTRODUCES PERIPHERAL RADIOLOGY PRODUCTS
CORDIS INTRODUCES PERIPHERAL RADIOLOGY PRODUCTS
CORDIS INTRODUCES PERIPHERAL RADIOLOGY PRODUCTS
TWO NEW CORDIS ANGIOPLASTY CATHETERS GAIN U.S. MARKET RELEASE
FOUR CORDIS ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE
ANOTHER CORDIS ANGIOPLASTY CATHETER APPROVED FOR US MARKET RELEASE
CORDIS INTRODUCES NEW ANGIOPLASTY CATHETER LINE
CORDIS MAGNETIC RAPID-EXCHANGE SYSTEM GAINS FDA APPROVAL

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters